LUCID DIAGNOSTICS DL-.001 Aktie

Lucid Diagnostics reported Q2 2026 revenue of $1.47 million (about 17% sequential) and a loss of $0.06 per share, each roughly in line with expectations. The company performed 2,770 EsoGuard tests and sees progress on reimbursement from Medicare, the VA and commercial insurers, but remains dependent on inconsistent reimbursement decisions. Cash and cash equivalents stood at $33.4 million, cash burn was $11.3 million; management emphasizes focusing on expanding reimbursement before making price adjustments. » More on de.investing.com

Lucid Diagnostics reports progress on reimbursement for its EsoGuard test (ConcertAI coverage, recognition in United and Cigna guidelines, inclusion in the VA Federal Supply Schedule), but is still awaiting a Medicare Local Coverage Determination. The company has performed about 60,000 tests and runs a quarterly volume of 2,500–3,000 tests; it expects per-test costs under $200 at scale and a potential gross margin of 80% at a Medicare reimbursement rate of $1,900. After securing Medicare approval, Lucid plans aggressive commercialization, VA contract signings and possibly another funding round to accelerate growth. » More on de.investing.com

Lucid Diagnostics completed a guaranteed, registered direct placement of 18 million common shares at $1.00 per share. One institutional investor contributed $15 million and an existing shareholder also participated; gross proceeds are approximately $18 million before discounts and fees. Net proceeds are intended for working capital and general corporate purposes; Canaccord Genuity and BTIG served as bookrunners and the offering was made pursuant to an S-3 registration. » More on de.investing.com